-+ 0.00%
-+ 0.00%
-+ 0.00%

CervoMed says Phase 2a nfvPPA trial of neflamapimod reduces plasma NfL over 12 weeks

PUBT·10/12/2026 11:32:04
CervoMed says Phase 2a nfvPPA trial of neflamapimod reduces plasma NfL over 12 weeks
  • CervoMed disclosed initial Phase 2a results for neflamapimod in nonfluent variant primary progressive aphasia, presented at ISFTD 2026.
  • Early biomarker readouts showed a reduction in a key blood marker tied to neurodegeneration during the first 12 weeks of treatment.
  • A second biomarker linked to neuroinflammation remained broadly stable over the same period.
  • Safety looked generally manageable, with one discontinuation tied to elevated liver enzymes that resolved once dosing stopped.
  • Additional 24-week biomarker data will be presented in November 2026; topline clinical results are expected in Q1 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cervomed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610120730PRIMZONEFULLFEED9843621) on October 12, 2026, and is solely responsible for the information contained therein.